Medicine and manufacturing technology provider Novanta (NASDAQ: NOVT) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 10.4% year on year to $257.7 million. Guidance for next quarter’s revenue was better than expected at $261.5 million at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 4.3% above analysts’ consensus estimates.

Is now the time to buy NOVT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Novanta’s first quarter saw a strong positive market reaction, reflecting confidence in management’s execution and commercial momentum. The company credited broad-based demand and robust bookings, particularly in the Robotics & Automation and Advanced Surgery businesses, as central to its performance. CEO Matthijs Glastra highlighted that every segment achieved double-digit bookings growth, with new product revenue rising sharply. Management specifically pointed to ongoing strength in medical consumables and accelerating opportunities in Generative AI (GenAI)-related manufacturing applications as key factors supporting both revenue and profit growth.

Looking ahead, Novanta’s guidance is shaped by expectations for continued acceleration in high-growth end markets, especially AI-driven robotics, precision manufacturing, and medical consumables. Management is focused on offsetting recent tariff and freight cost headwinds through repricing and cost reduction measures, with CFO Robert Buckley stating that “these additional actions, combined with our site closures, will put our gross margins back on track.” The company’s outlook is supported by a strong bookings backlog, new product launches, and ongoing investments in manufacturing efficiency and M&A opportunities.

Key Insights from Management’s Remarks

Management attributed the company’s Q1 performance to strong new product launches, increased demand across medical and automation markets, and effective commercial execution despite a volatile cost environment.

• New product momentum: Revenue from recently launched products grew over 50% year-over-year, raising the Vitality Index—the share of sales from products launched in the past five years—to 27%. This surge was most pronounced in Advanced Surgery and Robotics & Automation, supporting both top-line growth and customer retention.

• AI and semiconductor tailwinds: Applications tied to GenAI infrastructure—including deep UV and extreme UV lithography, GPU drilling, and advanced packaging—accounted for roughly 15% of total sales and grew 20% year-over-year. Management expects this portion to accelerate further as AI-driven manufacturing demand expands.

• Medical consumables as a growth engine: The medical consumables franchise now represents about 15% of revenue and continues to grow at a double-digit rate, driven by strong demand for next-generation insufflators and related products in minimally invasive and robotic surgery markets.

• Regional manufacturing consolidation: Two facility closures are on track for Q2 completion as part of Novanta’s regional manufacturing initiative. Management expects this consolidation to drive gross margin improvement in the second half of the year through enhanced scale and operational efficiency.

• Tariffs and cost inflation: A rapid escalation in tariffs, particularly on materials like aluminum, along with higher freight costs, pressured Q1 margins. Management responded by implementing product price increases and updated surcharges, with most of these adjustments expected to benefit results from Q3 onwards.

Drivers of Future Performance

Novanta’s outlook is anchored by ongoing demand in AI-enabled markets, new product launches, and cost mitigation strategies to combat margin headwinds.

• AI and automation demand: Management anticipates sustained growth in Robotics & Automation and Precision Manufacturing, fueled by rising adoption of AI-driven solutions in manufacturing and data centers. Expansion in GenAI applications is expected to remain a significant contributor to top-line growth.

• Margin recovery initiatives: The company is pursuing repricing efforts, updated surcharges, and regional manufacturing consolidation to counteract higher tariffs and freight costs. Management believes these actions will result in sequential margin improvement, particularly in the second half of the year.

• Active M&A pipeline: Novanta continues to prioritize acquisitions that expand its presence in medical technologies and consumables, aiming to diversify revenue streams and reduce cyclicality. Management indicated a strong pipeline of opportunities, with disciplined capital allocation guiding future deals.

Catalysts in Upcoming Quarters

In the upcoming quarters, our analysts will be watching (1) the pace of gross margin recovery as repricing and cost actions take effect, (2) continued double-digit growth in medical consumables and AI-driven automation segments, and (3) execution on the regional manufacturing consolidation initiative. Additionally, we will monitor the conversion of strong bookings into revenue and the progression of M&A activity as potential drivers of long-term growth.

Novanta currently trades at $158.01, up from $139.98 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.